Comparison of diagnostic utility between procalcitonin and C-reactive protein for the patients with blood culture-positive sepsis

Korean Journal of Laboratory Medicine

Volumn 29, Issue 6, 2009, Pages 529-535

  Hur, Mina ^a   Moon, Hee Won ^a   Yun, Yeo Min ^a   Kim, Kyung Hee ^b   Kim, Hyun Soo ^b   Lee, Kyu Man ^b  

^a Konkuk University School of Medicine   (South Korea)

^b Hallym University College of Medicine   (South Korea)

Author keywords

C reactive protein; Procalcitonin; Sepsis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCITONIN; PROCALCITONIN; PROTEIN PRECURSOR;

ADOLESCENT; ADULT; AGED; ANALYTICAL EQUIPMENT; ARTICLE; BLOOD; CHILD; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFANT; MIDDLE AGED; NEWBORN; PHOTOMETRY; PRESCHOOL CHILD; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEPSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PROTEIN PRECURSORS; REAGENT KITS, DIAGNOSTIC; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEPSIS;

EID: 77951449494     PISSN: 15986535     EISSN: None     Source Type: Journal    
DOI: 10.3343/kjlm.2009.29.6.529     Document Type: Article

References (27)

1. Pfäfflin A and Schleicher E. Inflammation markers in point-of-care testing (POCT). Anal Bioanal Chem 2009;393:1473-80.
2. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
3. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6.
4. Mitaka C. Clinical laboratory differentiation of infectious versus noninfectious systemic inflammatory response syndrome. Clin Chim Acta 2005;351:17-29.
5. Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta 2002;323:17-29.
6. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008;36:941-52.
7. Chua AP and Lee KH. Procalcitonin in severe acute respiratory syndrome (SARS). J Infect 2004;48:303-6.
8. Cone JB. Inflammation. Am J Surg 2001;182:558-62.
9. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-45.
10. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39: 206-17.
11. Whicher J, Bienvenu J, Monneret G. Procalcitonin as an acute phase marker. Ann Clin Biochem 2001;38:483-93.
12. Nijsten MW, Olinga P, The TH, de Vries EG, Koops HS, Groothuis GM, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med 2000;28:458-61.
13. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341:515-8.
14. Brunkhorst FM, Al-Nawas B, Krummenauer F, Forycki ZF, Shah PM. Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia. Clin Microbiol Infect 2002;8:93-100.
15. Oberhoffer M, Vogelsang H, Russwurm S, Hartung T, Reinhart K. Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med 1999;37:363-8.
16. Rau BM, Frigerio I, Büchler MW, Wegscheider K, Bassi C, Puolakkainen PA, et al. Evaluation of procalcitonin for predicting septic multiorgan failure and overall prognosis in secondary peritonitis: a prospective, international multicenter study. Arch Surg 2007;142: 134-42.
17. Rau B, Krüger CM, Schilling MK. Procalcitonin: improved biochemical severity stratification and postoperative monitoring in severe abdominal inflammation and sepsis. Langenbecks Arch Surg 2004; 389:134-44.
18. Liaudat S, Dayer E, Praz G, Bille J, Troillet N. Usefulness of procalcitonin serum level for the diagnosis of bacteremia. Eur J Clin Microbiol Infect Dis 2001;20:524-7.
19. Whang KT, Steinwald PM, White JC, Nylen ES, Snider RH, Simon GL, et al. Serum calcitonin precursors in sepsis and systemic inflammation. J Clin Endocrinol Metab 1998;83:3296-301.
20. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006;34:1996-2003.
21. Boussekey N, Leroy O, Georges H, Devos P, d'Escrivan T, Guery B. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection 2005;33:257-63.
22. Thayyil S, Shenoy M, Hamaluba M, Gupta A, Frater J, Verber IG. Is procalcitonin useful in early diagnosis of serious bacterial infections in children? Acta Paediatr 2005;94:155-8.
23. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, et al. Diagnostic value of procalcitonin, interleukin-6 and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001;164:396-402.
24. Müller B, Becker KL, Schächinger H, Rickenbacher PR, Huber PR, Zimmerli W, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000;28:977-83.
25. Povoa P, Almeida E, Moreira P, Fernandes A, Mealha R, Aragao A, et al. C-reactive protein as an indicator of sepsis. Intensive Care Med 1998;24:1052-6.
26. Aikawa N, Fujishima S, Endo S, Sekine I, Kogawa K, Yamamoto Y, et al. Multicenter prospective study of procalcitonin as an indicator of sepsis. J Infect Chemother 2005;11:152-9.
27. Endo S, Aikawa N, Fujishima S, Sekine I, Kogawa K, Yamamoto Y, et al. Usefulness of procalcitonin serum level for the discrimination of severe sepsis from sepsis: a multicenter prospective study. J Infect Chemother 2008;14:244-9.